Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide in SCD-related Acute Chest Syndrome
NCT03805581Phase 2Completed
- Sponsor
- New York Medical College
- Start
- Jan 2018
- Primary completion
- Jul 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of defibrotide in acute chest syndrome (ACS), sponsored by New York Medical College. Primary endpoints: Number of patients with grade III/IV allergic reaction to defibrotide at 30 days and Number of patients with grade III/IV hemorrhage at 30 days. Started Jan 2018; status: completed.
02
Drugs
defibrotide
03
Conditions
acute chest syndrome (ACS)
Beyond the preview
Go deeper on NCT03805581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03805581.